Cel-Sci Corporation is a biotechnology company focused on the development of innovative immunotherapy products for the treatment of cancer and other life-threatening diseases. The company is primarily engaged in the research and development of its lead product candidate, which leverages the unique properties of the immune system to combat tumors. With a commitment to enhancing patient outcomes, Cel-Sci explores novel therapeutic approaches and collaborates with research institutions to advance its clinical programs, aiming to bring new hope to patients in need of effective treatment options. Read More
CEL-SCI Corporation (“CEL-SCI” or the “Company”) (NYSE American: CVM), a clinical stage cancer immunotherapy company, today announced the closing of its underwritten public offering of 2,000,000 shares of its common stock at a public offering price of $2.50 per share. Total gross proceeds from the offering, before deducting the underwriting discount and other offering expenses, were $5,000,000. In addition, the Company has granted the underwriters a 45-day option to purchase up to an additional 190,000 shares to cover over-allotments at the public offering price, less the underwriting discount.
Stay up-to-date with the latest market trends one hour before the close of the markets on Thursday. Explore the top gainers and losers during today's session in our detailed report.
Investors and traders are closely monitoring the gap up and gap down stocks in today's session on Thursday. Let's explore the market movements and identify the stocks with significant gaps.
CEL-SCI Corporation (“CEL-SCI” or the “Company”) (NYSE American: CVM), a clinical stage cancer immunotherapy company, today announced the pricing of an underwritten public offering of 2,000,000 shares of its common stock at a public offering price of $2.50 per share. Total gross proceeds from the offering, before deducting the underwriting discount and other offering expenses, are expected to be $5,000,000. In addition, the Company has granted the underwriters a 45-day option to purchase up to an additional 190,000 shares to cover over-allotments at the public offering price, less the underwriting discount. The offering is expected to close on May 23, 2025, subject to satisfaction of customary closing conditions.
CEL-SCI Corporation (“CEL-SCI” or the “Company”) (NYSE American: CVM), a clinical stage cancer immunotherapy company, today announced that it intends to offer to sell shares of its common stock (and/or pre-funded warrants (“Pre-Funded Warrants”) in lieu thereof) in an underwritten public offering. All of the shares of common stock (and/or Pre-Funded Warrants) are being offered by the Company. The offering is subject to market conditions and there can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering.
CEL-SCI Corporation (NYSE American: CVM) today announced it has completed its Breakthrough Medicine Designation application for Multikine* (Leukocyte Interleukin, Injection) for submission to the Saudi Food and Drug Authority (SFDA) in Saudi Arabia. Multikine is an immunotherapy administered before surgery as a treatment for newly diagnosed previously untreated head and neck cancer.
CEL-SCI Corporation (NYSE American: CVM) announced today that during its annual Shareholder’s Meeting on May 19, 2025, a combination was authorized for its outstanding shares of common stock. On May 19, 2025, the Board of Directors approved a 1 for 30 combination of common stock. CEL-SCI expects the combination to be implemented on May 20, 2025. When the market opens on May 20, 2025, the common stock will trade under a new CUSIP number 150837 706, but the Company's ticker symbol, CVM, will remain unchanged.
CEL-SCI Corporation (NYSE American: CVM) today reported financial results for the three months ended March 31, 2025, as well as key recent clinical and corporate developments.
CEL-SCI Corporation (NYSE American: CVM) today announced that it met with the Saudi Food and Drug Authority (SFDA) to discuss the development of Multikine cancer immunotherapy* (Leukocyte Interleukin, Injection), the vast amount of Multikine data available to support a marketing application for its use as a treatment of head and neck cancer, and the possible pathways to a marketing application in Saudi Arabia.
Wondering how the US markets performed in the middle of the day on Monday? Discover the movers and shakers of today's session in our comprehensive analysis.
CEL-SCI Corporation (NYSE American: CVM) today announced that a study titled “Distinct CD8+ T cell dynamics associate with response to neoadjuvant cancer immunotherapies” by Li Housaiyin et. al., Cancer Cell (2025) provides support for CEL-SCI’s approach aimed at seeking early regulatory approval for Multikine* (Leukocyte Interleukin, Injection) as a neoadjuvant in the treatment of newly diagnosed previously untreated locally advanced head and neck cancer based on early tumor responses.
